Examples of TAAs that have been identified and utilized in TCVs include cancer/germline antigens (e.g., MAGE-A1, MAGE-A3, and NY-ESO-1) [206]; cell lineage differentiation antigens (e.g., tyrosinase, MART-1, prostate-specific antigen) [207]; and overexpressed cancer antigens (e.g., hTERT, HER2, mesothelin, and MUC-1) [208]. This evidence concerns the gene MSLN and cancer.